Predict your next investment

HEALTHCARE | Biotechnology
sirna.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$9.9M

Valuation

$0000 

About Sirna Therapeutics

Sirna Therapeutics develops treatments based on RNAi technology for asthma, diabetes, hepatitis C, macular degeneration and Huntington's Disease.

Sirna Therapeutics Headquarter Location

185 Berry Street Suite 6504

San Francisco, California, 94107,

United States

Latest Sirna Therapeutics News

Novo to acquire Dicerna for more than $3B amid RNA drug resurgence

Nov 18, 2021

Published Nov. 18, 2021 Novo Nordisk Diabetes drug specialist Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals in a deal worth $3.3 billion, a strategic bet that an existing wide-ranging alliance between the two will yield multiple medicines for a range of diseases. Novo will pay $38.25 per share in cash for Dicerna, an 80% premium to the $21.28 closing price of the biotech's shares Wednesday. The boards of both companies have unanimously approved the deal, which is expected to close in the fourth quarter. The acquisition is the latest validation of so-called RNA interference drugs, a drugmaking method that involves silencing genes before they can make harmful proteins. The field, based on scientific work that won a Nobel Prize in 2006, drew significant interest from pharmaceutical companies many years ago because of its potential to create drugs capable of reaching disease targets other medicines couldn't. In the mid-2000s, large drugmakers jumped into RNAi. The field's largest company, Alnylam, for instance, struck big partnerships with Roche, Novartis and others. Merck & Co. acquired Sirna Therapeutics for $1.1 billion. But they left quickly thereafter after facing challenges delivering RNAi medicines into cells, a problem that took years to solve. Merck closed Sirna's labs, while Roche exited the field altogether, a move that sent shock waves through the field at the time. RNAi, however, has since had a renaissance. Alnylam won U.S. approval of the first RNAi drug, Onpattro, in 2018. Two other Alnylam drugs for rare conditions have followed and another it discovered, now owned by Novartis, is cleared in Europe to treat certain types of high cholesterol. In the meantime, larger companies have cozied back up to RNAi drugmakers. Johnson & Johnson, for instance, promised up to $3.7 billion in an alliance with Arrowhead Pharmaceuticals struck in late 2017. And Dicerna, which has been around since 2006 but hasn't yet developed a marketed drug, signed a string of licensing deals with Eli Lilly, Roche, Alexion and others. Among those deals was a partnership with Novo, through which the two aimed to develop treatments for chronic liver diseases and cardiometabolic conditions like obesity, NASH and Type 2 diabetes. None of those treatments are in human testing — incidentally, cardiometabolic Dicerna drugs owned by Novo's main rival, Lilly, are further along. The first human trial from the collaboration should begin next year. Follow Ben Fidler on Twitter

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sirna Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sirna Therapeutics is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sirna Therapeutics Patents

Sirna Therapeutics has filed 134 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • Gene expression
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/6/2018

12/7/2021

RNA, MicroRNA, Molecular biology, Gene expression, RNA interference

Grant

Application Date

4/6/2018

Grant Date

12/7/2021

Title

Related Topics

RNA, MicroRNA, Molecular biology, Gene expression, RNA interference

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.